Propanc Biopharma Receives Nasdaq Delisting Notice

Article summary

Propanc Biopharma has received a notice from Nasdaq indicating that its stock failed to meet the minimum bid price requirement and is ineligible for a standard compliance period due to a recent reverse stock split.